SCHEMBL31744988

SCHEMBL31744988

CCCCCCCCCCCCCCCCO[C@@H]1[C@H](OP(O)(O)=S)[C@@H](CO)O[C@H]1n1cnc2c(N)ncnc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 2/20 0.57
▸ EHMT1 Q9H9B1 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ ADORA2A P29274 3/20 0.52
▸ ADORA2B P29275 3/20 0.52
▸ ADORA3 P0DMS8 3/20 0.52
▸ PI4KA P42356 2/20 0.52
▸ PI4K2B Q8TCG2 2/20 0.52
▸ PI4K2A Q9BTU6 2/20 0.52
▸ PI4KB Q9UBF8 2/20 0.52
▸ DPP4 P27487 1/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ SLC28A1 O00337 1/20 0.52
▸ MAP3K7 O43318 1/20 0.52
▸ SLC28A2 O43868 1/20 0.52
▸ GAPDH P04406 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ STAT6 P42226 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32676286 0.91 ADORA1 (0.70) ADORA1SMN1; SMN2
SCHEMBL29495154 0.91 ADORA1 (0.70) ADORA1SMN1; SMN2
SCHEMBL22582756 0.91 ADORA1 (0.70) ADORA1SMN1; SMN2
SCHEMBL11133383 0.90 EHMT1 (0.62) ADORA1EHMT1GAAADORA2AADORA2B
SCHEMBL10590814 0.90 EHMT1 (0.62) ADORA1EHMT1GAAADORA2AADORA2B
SCHEMBL30583012 0.89 ADORA1 (0.62) ADORA1GAAADORA2AADORA2BADORA3
SCHEMBL15329251 0.89 ADORA1 (0.62) ADORA1GAAADORA2AADORA2BADORA3
SCHEMBL21314872 0.86 ADORA1 (0.64) ADORA1GAAADORA2AADORA2BADORA3
SCHEMBL15329393 0.86 ADORA1 (0.64) ADORA1GAAADORA2AADORA2BADORA3
SCHEMBL29384896 0.86 ADORA1 (0.64) ADORA1GAAADORA2AADORA2BADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382324-A1 MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC. (US) 2025-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382324-A1 MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES POLM, PCNA, POLRMT ADORA1 3733/4885EHMT1 1618/4885GAA 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback